Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver Bioscience that is designed to advance novel therapies for genetic epilepsies and could garner up to $120 ...

Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience ("Quiver"), a discovery technology and therapeutics company advancing programs for the treatment of central ...

CAMBRIDGE, Mass., July 01, 2025--(BUSINESS WIRE)--Quiver Bioscience ("Quiver"), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) ...

Bow quivers don’t get a lot of love, but they should. Many archers will drop over a grand on a new flagship bow and outfit it with a fancy sight, drop-away rest, and even add a pricy front- and ...

Angelini Pharma and Quiver Bioscience enter research collaboration and licensing pact to discover and advance novel therapeutics for genetic epilepsies: Rome Wednesday, February 2 ...